Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with a variety of frontotemporal dementia (FTD). To pivot away from latozinemab, the Bay Area biotech is laying off 49% of its staff, while the company’s president and head of R&D Sara Kenkare-Mitra, Ph.D., is resigning.
